Artrya’s Salix platform goes live at Northeast Georgia Health System, triggering revenue generation
Artrya Limited (ASX: AYA) has confirmed that its Salix platform is now in live clinical use at Northeast Georgia Health System (NGHS), with the first patient scans now processed and revenue generation underway.
The Australian medical technology company commercialises the Salix AI-powered cloud platform for the real-time, point-of-care assessment and management of coronary artery disease. This go-live marks Artrya’s second U.S. customer moving into active clinical deployment.
The milestone shifts the company from contracted deployment to active revenue generation. Salix is now operating in the first of NGHS’s five hospitals and outpatient facilities, with roll-out to the remaining sites planned in the near term.
When big ASX news breaks, our subscribers know first
What went live — the first NGHS site and the Salix modules in use
The Salix platform is live at the first of NGHS’s five hospital and outpatient facilities. Artrya has indicated it will support roll-out across all five hospitals in the NGHS network in the near term.
Two modules are now in routine clinical use. The Salix Coronary Anatomy platform is licensed as a SaaS platform, generating monthly subscription fees. The Salix Coronary Plaque module generates fee-per-scan revenue as coronary CT angiography (CCTA) scans are analysed for patients presenting with suspected or confirmed coronary artery disease.
A third module, Salix Coronary Flow, is expected to be activated for clinical use once FDA cleared, at which point it would generate additional fee-per-scan revenue. This module remains pending FDA clearance.
Clinical scale at the site is notable. Georgia Heart Institute, described as one of the largest cardiology programs in the state, serves more than 100,000 patients annually and is now using Salix output as part of its routine diagnostic workflow.
| Module | Function | Revenue Model | Status |
|---|---|---|---|
| Salix Coronary Anatomy | Coronary anatomy assessment | SaaS monthly subscription | Live |
| Salix Coronary Plaque | Plaque assessment from CCTA scans | Fee-per-scan | Live |
| Salix Coronary Flow | Coronary flow assessment | Fee-per-scan | Pending FDA clearance |
Understanding coronary CTA and why Salix matters to investors
Artrya’s proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently.
For investors, the significance lies in the revenue structure. The dual model combines a recurring SaaS subscription with per-scan fees.
Why this milestone strengthens the investment case
The NGHS go-live represents a transition from a contracted customer to a revenue-generating deployment, a step change in how the relationship contributes to the company’s financial profile.
Key points from the update include:
-
Artrya’s second U.S. customer is now live and generating revenue.
-
The roll-out path to all five NGHS hospitals in the near term is expected to expand the revenue base.
-
Management cited strong early clinical engagement as underpinning growing adoption.
Artrya’s U.S. commercial push extends beyond hospital deployment agreements, with the SAPPHIRE Study designed to build real-world evidence across multiple health systems in support of broader clinical adoption and reimbursement pathway development.
- Artrya reported it is on track for all three U.S. foundation partners to be commercial in the near future.
No specific revenue figures were disclosed in the announcement.
John Konstantopoulos, Co-Founder and CEO, Artrya
“The team has worked incredibly hard to successfully integrate Salix and train the clinical team at NGHS over these last few months. We are all excited to see the Georgia Heart Institute’s cardiologists using Salix on real patients across their first site and build their confidence in the product. We’re already seeing strong clinical engagement that should underpin growing adoption, and we aim to have Cone Health online in the near future.”
What comes next
The near-term roadmap centres on expanding the Salix roll-out across all five NGHS hospitals. Beyond the initial site, Artrya intends to support deployment throughout the wider network.
Konstantopoulos referenced a target to bring Cone Health online in the near future. The company also reported it is on track for all three U.S. foundation partners to be commercial in the near future.
The Salix Coronary Flow module is expected to be activated for revenue once FDA cleared, adding a further fee-per-scan revenue stream to the two modules already live.
With its second U.S. customer now generating revenue and a defined roll-out ahead, the NGHS go-live moves Artrya a step closer to broader commercialisation across its U.S. footprint.
Don’t Miss the Next Healthcare Breakout
Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis. Over 20,000 investors already rely on Big News Blast to stay ahead of market-moving announcements the moment they drop. Click the “Free Alerts” button to start receiving alerts before the market has a chance to react.